Modular Medical, Inc.

Item 1.01 Entry into a Material Definitive Agreement. On April 19, 2026, Modular Medical, Inc. (the “Company”) entered into a Placement Agency Agreement (the “Agreement”) with Maxim Group LLC (the “Placement Agent”), relating to a registered direct offering (the “Offering”) of 750,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), referred to as the “Shares.” The gross proceeds to the Company from the Offering will be approximately $3.375 million, before deducting the Placement Agent fee and other offering expenses. The Offering is expected to close on April 21, 2026 (the “Closing Date”). Pursuant to the Agreement, the Company agreed to pay the Placement Agent a cash fee equal to 7% of the gross proceeds received from the Offering and to reimburse the Placement Agent for its expenses incurred in connection with the Offering in an amount up to $75,000. The Offering was made pursuant to an effective registration statement on Form S-3 (Registration Statement No. 333- 287313) previously filed with the Securities and Exchange Commission (the “SEC”) on May 15, 2025 and declared effective by the SEC on May 22, 2025, and a final prospectus supplement relating to the Offering dated April 19, 2026. Pursuant to the Agreement, each of the Company’s directors and executive officers entered into “lock-up” agreements that, subject to certain exceptions, prohibit, without the prior written consent of the Placement Agent, the sale, transfer, or other disposition of securities of the Company for a period of 90 days from the date of the Agreement. Pursuant to the Agreement, the Company has agreed not to, subject to certain conditions and exceptions, offer, pledge, sell, contract to sell, or sell any option, right or warrant to purchase, lend or otherwise transfer or dispose, directly or indirectly, any shares of capital stock or any securities convertible into or exercisable or exchangeable for shares of capital stock, affect or enter into an agreement to effect any issuance by the Company or its subsidiaries of Common Stock or Common Stock equivalents (or a combination of units thereof) for a period of 45 days from the Closing Date. The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference. A copy of the legal opinion of Lucosky Brookman, LLP relating to the Shares is attached hereto as Exhibit 5.1. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Item 8.01 Other Events. The Company issued a press release announcing the pricing of the Offering on April 19, 2026. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits (d) Exhibits The following exhibits are filed with this report: Exhibit Exhibit Description Number ──────────────────────────────────────────────────────────────────────────────────────────────────────────────── 1.1 Placement Agency Agreement, dated as of April 19, 2026, between the Company and Maxim Group LLC 5.1 Opinion of Lucosky Brookman, LLP 23.1 Consent of Lucosky Brookman, LLP (included in Exhibit 5.1) 99.1 Press Release dated April 19, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)